Our results presented in the current study show that Tim-3 blockage significantly enhances primary NK cells and NK cell line mediated-killing of MM cells in vitro and in vivo, supporting the notion that Tim-3 may be an important target molecule used for developing an antibody and/or NK cell based immunotherapeutic strategies for MM. This evidence concerns the gene HAVCR2 and Miyoshi myopathy.